30-Day Federal Register Notice

Federal Register / Vol. 87, No. 62 / Thursday, March 31, 2022 / Notices
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
All comments submitted in response
to this notice are a matter of public
record. USPTO will include or
summarize each comment in the request
to OMB to approve this information
collection. Before including an address,
phone number, email address, or other
personal identifying information (PII) in
a comment, be aware that the entire
comment—including PII—may be made
publicly available at any time. While
you may ask in your comment to
withhold PII from public view, USPTO
cannot guarantee that it will be able to
do so.
Kimberly Hardy,
Information Collections Officer, Office of the
Chief Administrative Officer, United States
Patent and Trademark Office.
[FR Doc. 2022–06765 Filed 3–30–22; 8:45 am]
BILLING CODE 3510–16–P

COMMODITY FUTURES TRADING
COMMISSION
Agency Information Collection
Activities: Notice of Intent To Extend
Collection 3038–0084: Regulations
Establishing and Governing the Duties
of Swap Dealers and Major Swap
Participants
Commodity Futures Trading
Commission.
ACTION: Notice.
AGENCY:

In compliance with the
Paperwork Reduction Act of 1995
(‘‘PRA’’), this notice announces that the
Information Collection Request (‘‘ICR’’)
abstracted below has been forwarded to
the Office of Information and Regulatory
Affairs (‘‘OIRA’’), of the Office of
Management and Budget (‘‘OMB’’), for
review and comment. The ICR describes
the nature of the information collection
and its expected costs and burden.
DATES: Comments must be submitted on
or before May 2, 2022.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be
submitted within 30 days of this
notice’s publication to OIRA, at https://
www.reginfo.gov/public/do/PRAMain.
Please find this particular information
collection by selecting ‘‘Currently under
30-day Review—Open for Public
Comments’’ or by using the website’s
search function. Comments can be
entered electronically by clicking on the

jspears on DSK121TN23PROD with NOTICES1

SUMMARY:

VerDate Sep<11>2014

18:38 Mar 30, 2022

Jkt 256001

‘‘comment’’ button next to the
information collection on the ‘‘OIRA
Information Collections Under Review’’
page, or the ‘‘View ICR—Agency
Submission’’ page. A copy of the
supporting statement for the collection
of information discussed herein may be
obtained by visiting https://
www.reginfo.gov/public/do/PRAMain.
In addition to the submission of
comments to https://Reginfo.gov as
indicated above, a copy of all comments
submitted to OIRA may also be
submitted to the Commodity Futures
Trading Commission (the
‘‘Commission’’ or ‘‘CFTC’’) by clicking
on the ‘‘Submit Comment’’ box next to
the descriptive entry for OMB Control
No. 3038–0084, at https://
comments.cftc.gov/FederalRegister/
PublicInfo.aspx.
Or by either of the following methods:
• Mail: Christopher Kirkpatrick,
Secretary of the Commission,
Commodity Futures Trading
Commission, Three Lafayette Centre,
1155 21st Street NW, Washington, DC
20581.
• Hand Delivery/Courier: Same as
Mail above.
All comments must be submitted in
English, or if not, accompanied by an
English translation. Comments
submitted to the Commission should
include only information that you wish
to make available publicly. If you wish
the Commission to consider information
that you believe is exempt from
disclosure under the Freedom of
Information Act, a petition for
confidential treatment of the exempt
information may be submitted according
to the procedures established in § 145.9
of the Commission’s regulations.1 The
Commission reserves the right, but shall
have no obligation, to review, prescreen, filter, redact, refuse or remove
any or all of your submission from
https://www.cftc.gov that it may deem to
be inappropriate for publication, such as
obscene language. All submissions that
have been redacted or removed that
contain comments on the merits of the
ICR will be retained in the public
comment file and will be considered as
required under the Administrative
Procedure Act and other applicable
laws, and may be accessible under the
Freedom of Information Act.
FOR FURTHER INFORMATION CONTACT:
Philip Newsom, Attorney Advisor,
Market Participants Division,
Commodity Futures Trading
Commission, Three Lafayette Centre,
1155 21st Street NW, Washington, DC
20581; (202) 418–5301; email:
[email protected].
1 17

PO 00000

CFR 145.9.

Frm 00008

Fmt 4703

Sfmt 4703

18771

SUPPLEMENTARY INFORMATION:

Title: Regulations Establishing and
Governing the Duties of Swap Dealers
and Major Swap Participants (OMB
Control No. 3038–0084). This is a
request for an extension of a currently
approved information collection.
Abstract: On April 3, 2012 the
Commission adopted Commission
regulations 23.600 (Risk Management
Program), 23.601 (Monitoring of
Position Limits), 23.602 (Diligent
Supervision), 23.603 (Business
Continuity and Disaster Recovery),
23.606 (General Information:
Availability for Disclosure and
Inspection), and 23.607 (Antitrust
Considerations) 2 pursuant to section
4s(j) 3 of the Commodity Exchange Act
(‘‘CEA’’). The above regulations adopted
by the Commission require, among other
things, swap dealers (‘‘SD’’) 4 and major
swap participants (‘‘MSP’’) 5 to develop
a risk management program (including a
plan for business continuity and
disaster recovery and policies and
procedures designed to ensure
compliance with applicable position
limits). The Commission believes that
the information collection obligations
imposed by the above regulations are
essential to ensuring that swap dealers
and major swap participants maintain
adequate and effective risk management
programs and policies and procedures
to ensure compliance with position
limits.
An agency may not conduct or
sponsor, and a person is not required to
respond to, a collection of information
unless it displays a currently valid OMB
control number. On January 28, 2022,
the Commission published in the
Federal Register notice of the proposed
extension of this information collection
and provided 60 days for public
comment on the proposed extension, 87
FR 4567 (‘‘60-Day Notice’’). The
Commission did not receive any
relevant comments on the 60-Day
Notice.
Burden Statement: The Commission
is revising its estimate of the burden for
this collection to reflect the current
number of respondents and estimated
burden hours. The respondent burden
for this collection is estimated to be as
follows:
Estimated Number of Respondents:
107.
2 17 CFR 23.600, 23.601, 23.602, 23.603, 23.606,
and 23.607.
3 7 U.S.C. 6s(j).
4 For the definition of SD, see section 1a(49) of
the CEA and Commission regulation 1.3. 7 U.S.C.
1a(49) and 17 CFR 1.3.
5 For the definitions of MSP, see section 1a(33) of
the CEA and Commission regulation 1.3. 7 U.S.C.
1a(33) and 17 CFR 1.3.

E:\FR\FM\31MRN1.SGM

31MRN1

18772

Federal Register / Vol. 87, No. 62 / Thursday, March 31, 2022 / Notices

Estimated Average Burden Hours per
Respondent: 1,148.5 hours.
Estimated Total Annual Burden
Hours: 122,889.5 hours.
Frequency of Collection: As
applicable.
There are no capital costs or operating
and maintenance costs associated with
this collection.
(Authority: 44 U.S.C. 3501 et seq.)
Dated: March 25, 2022.
Robert Sidman,
Deputy Secretary of the Commission.
[FR Doc. 2022–06751 Filed 3–30–22; 8:45 am]
BILLING CODE 6351–01–P

CONSUMER PRODUCT SAFETY
COMMISSION
[Docket No. CPSC–2021–0006]

Notice of Availability: Final Guidance
on Alternative Test Methods and
Integrated Testing Approaches
U.S. Consumer Product Safety
Commission.
ACTION: Notice of availability.
AGENCY:

The Consumer Product Safety
Commission (Commission or CPSC) is
announcing the availability of a
document titled, ‘‘Final Guidance for
Industry and Test Method Developers:
CPSC Staff Evaluation of Alternative
Test Methods and Integrated Testing
Approaches and Data Generated from
Such Methods to Support FHSA
Labeling Requirements.’’
FOR FURTHER INFORMATION CONTACT: John
Gordon, Toxicologist, Directorate for
Health Sciences, U.S. Consumer Product
Safety Commission, 5 Research Place,
Rockville, MD 20850; telephone: 301–
987–2025; email: [email protected].
SUPPLEMENTARY INFORMATION: The
Federal Hazardous Substances Act
(FHSA), 15 U.S.C. 1261–1275, requires
that hazardous substances bear certain
cautionary statements on their labels.
Manufacturers may perform
toxicological tests to determine whether
such products require cautionary
labeling addressing the hazard.
Although animals are still used in
toxicological testing, most governmental
agencies support reduced use of animals
in testing, by promoting the acceptance
of data from alternative test methods.
In 1997, the National Institute of
Environmental Health Sciences
(NIEHS), the National Toxicology
Program (NTP), and 13 federal agencies
(including CPSC) joined to form the
Interagency Coordinating Committee for
the Validation of Alternative Methods
(ICCVAM). ICCVAM sponsors scientific

jspears on DSK121TN23PROD with NOTICES1

SUMMARY:

VerDate Sep<11>2014

18:38 Mar 30, 2022

Jkt 256001

review of non-animal tests (known as
New Approach Methodologies or
NAMs) that may reduce, refine, or
replace animal tests in evaluating
potential hazards. Reviews from
ICCVAM and other federal agencies can
provide a basis for regulatory agencies,
such as CPSC, to consider non-animal
testing alternatives for use in regulatory
decision making. In the past, CPSC staff
relied upon ICCVAM’s validation of
new alternative testing methods, as
reliable test methods to determine
compliance with the labeling
requirements of the FHSA. However,
ICCVAM no longer validates test
methods.
In 2012, CPSC issued a policy on nonanimal or alternative testing methods to
support labeling requirements under the
FHSA, as codified under 16 CFR
1500.232 (Animal Testing Policy).
CPSC’s website lists current CPSCaccepted alternative test methods and
their conditions of use.1 Since 2012,
new advancements in toxicological
testing, and in particular with NAMs,
have occurred. NAMs include in vitro
(in test tube), in chemico (all chemical
test, no biological material), or in silico
(computer models) methods and
approaches used to test for toxicological
effects in place of animal testing. In
some cases, NAMs are combined with
other NAMs or existing in vivo (animal)
data to form an ‘‘integrated approach to
testing and assessment’’ (IATAs).
The Commission reaffirms its policy
to find alternatives to traditional animal
testing that replace animals, reduce the
number of animals tested, and decrease
the pain and suffering in animals
associated with testing household
products. As such, the Commission
strongly encourages all agency
stakeholders to submit for evaluation by
CPSC staff any scientifically validated
alternative test methods that do not
require animal testing for determining
compliance with the labeling
requirements under the FHSA.
Because ICCVAM no longer validates
test methods, to assist stakeholders,
including the public, manufacturers,
test method developers, and test
laboratories in determining what test
methods are deemed reliable for
determining compliance with the
labeling requirements under the FHSA,
on March 31, 2021, the Commission
published a Notice of Availability in the
Federal Register and requested
comments on ‘‘Proposed Guidance for
Industry and Test Method Developers:
1 https://www.cpsc.gov/Business—
Manufacturing/Testing-Certification/
Recommended-Procedures-Regarding-the-CPSCsPolicy-on-Animal-Testing/.

PO 00000

Frm 00009

Fmt 4703

Sfmt 9990

CPSC Staff Evaluation of Alternative
Test Methods and Integrated Testing
Approaches and Data Generated from
Such Methods to Support FHSA
Labeling Requirements’’ 86 FR 16704.
CPSC received five comments that are
addressed in the staff’s briefing package
on the final guidance. The staff’s
briefing package is available on CPSC’s
website at NAM Final Guidance BVS
(cpsc.gov).
The CPSC has finalized its guidance
for industry and test method
developers.2 The final guidance informs
the public of staff’s informational
requirements and process for evaluating
NAMs and IATAs. The final guidance
does not prescribe a specific form of
validation and explains that validation
can be accomplished via several
different processes. A method’s
reliability includes reproducibility,
repeatability, and robustness. In
addition to the performance and
applicability of the NAM/IATA, good
scientific, technical, and quality
practices will ensure that the overall
process is more efficient and effective
and leads to increased confidence in the
proposed method. The final guidance
also includes an optional NAM
nomination form that can be used to
organize information about a NAM or
IATA for evaluation by CPSC staff. Such
non-animal alternative test methods, if
accepted by CPSC, would be considered
reliable test methods for determining
compliance with the labeling
requirements under the FHSA.
Additionally, CPSC would continue to
list CPSC-accepted alternative test
methods on CPSC’s website.
The final guidance will be available
at: https://www.regulations.gov under
docket number, CPSC–2021–0006,
under ‘‘Supporting and Related
Material,’’ and on the Commission’s
website at: https://www.cpsc.gov/
Business--Manufacturing/TestingCertification/RecommendedProcedures-Regarding-the-CPSCsPolicy-on-Animal-Testing.
Alberta E. Mills,
Secretary, Consumer Product Safety
Commission.
[FR Doc. 2022–06825 Filed 3–30–22; 8:45 am]
BILLING CODE 6355–01–P

2 The Commission voted 4–0 to approve this
notice.

E:\FR\FM\31MRN1.SGM

31MRN1